Hsp90: a novel target for the disruption of multiple signaling cascades
- PMID: 17979631
- DOI: 10.2174/156800907780809778
Hsp90: a novel target for the disruption of multiple signaling cascades
Abstract
The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anti-cancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Similar articles
-
The therapeutic target Hsp90 and cancer hallmarks.Curr Pharm Des. 2013;19(3):347-65. doi: 10.2174/138161213804143725. Curr Pharm Des. 2013. PMID: 22920906 Free PMC article. Review.
-
Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.Expert Opin Ther Pat. 2011 Oct;21(10):1501-42. doi: 10.1517/13543776.2011.594041. Epub 2011 Jun 21. Expert Opin Ther Pat. 2011. PMID: 21689065 Review.
-
HSP90: a rising star on the horizon of anticancer targets.Future Oncol. 2005 Aug;1(4):529-40. doi: 10.2217/14796694.1.4.529. Future Oncol. 2005. PMID: 16556029 Review.
-
Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.Anticancer Res. 2009 Mar;29(3):797-807. Anticancer Res. 2009. PMID: 19414312 Review.
-
Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.J Pharm Pharmacol. 2018 Feb;70(2):151-158. doi: 10.1111/jphp.12824. Epub 2017 Oct 4. J Pharm Pharmacol. 2018. PMID: 28980313 Review.
Cited by
-
mTOR: An attractive therapeutic target for osteosarcoma?Oncotarget. 2016 Aug 2;7(31):50805-50813. doi: 10.18632/oncotarget.9305. Oncotarget. 2016. PMID: 27177330 Free PMC article. Review.
-
Pharmacological targeting of the Hsp70 chaperone.Curr Top Med Chem. 2009;9(15):1337-51. doi: 10.2174/156802609789895674. Curr Top Med Chem. 2009. PMID: 19860737 Free PMC article. Review.
-
Hsp90 inhibition: elimination of shock and stress.Bioorg Med Chem Lett. 2010 Sep 1;20(17):4983-7. doi: 10.1016/j.bmcl.2010.06.108. Epub 2010 Jul 1. Bioorg Med Chem Lett. 2010. PMID: 20656483 Free PMC article.
-
Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance.Cells. 2022 Sep 6;11(18):2778. doi: 10.3390/cells11182778. Cells. 2022. PMID: 36139353 Free PMC article. Review.
-
GALNT5 uaRNA promotes gastric cancer progression through its interaction with HSP90.Oncogene. 2018 Aug;37(33):4505-4517. doi: 10.1038/s41388-018-0266-4. Epub 2018 May 10. Oncogene. 2018. PMID: 29743591
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources